Administration of Zepatier (Grazoprevir Plus Elbasvir) in Chronic Hemodialysis (HD) Patients With Hepatitis C
Status:
Completed
Trial end date:
2020-09-01
Target enrollment:
Participant gender:
Summary
This is a study to define strategies for Nephrologists to directly supervise and apply direct
acting antivirals to cure hepatitis C in hemodialysis patients. Strategies will include
identification of candidate patients, application for insurance approval, specifics of direct
acting antiviral therapy (Zepatier with or without ribavirin) and laboratory monitoring
during and after therapy.
Phase:
Phase 4
Details
Lead Sponsor:
University of Pennsylvania
Collaborator:
Merck Sharp & Dohme Corp.
Treatments:
Elbasvir-grazoprevir drug combination Grazoprevir Ribavirin